Brief: MyMD Announces Preclinical Study Results Showing Supera-CBD Reduced Acute Inflammatory Pain
19/10/2023 14:19
Oct 19 (Reuters) - MyMD Pharmaceuticals Inc MYMD.O :
* MYMD ANNOUNCES PRECLINICAL STUDY RESULTS SHOWING NOVEL
CANNABIDIOL ANALOG, SUPERA-CBD™, REDUCED ACUTE INFLAMMATORY PAIN
* MYMD PHARMACEUTICALS - SUPERA-CBD EASED HEAT-RELATED PAIN
DUE TO
INFLAMMATION QUICKLY AND PROVIDED LONG-LASTING PAIN RELIEF
LASTING UP TO FIVE HOURS
* MYMD PHARMACEUTICALS INC - RESULTS SUGGEST SUPERA-CBD MAY
TARGET
SPECIFIC PAIN PATHWAYS, LESSENING POTENTIAL FOR SIDE EFFECTS
Source text for Eikon: ID:nBw112L32a
Further company coverage: MYMD.O
((Reuters.Briefs@thomsonreuters.com;))